Ovarian Cancer Quiz

Quiz

Quiz: Germline BRCA Testing in Ovarian Cancer

07/12/2022

True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.

True or False: About 34% of...

07/12/2022

Journal of Clinical Pathways

Quiz

Quiz: Cost-Effectiveness of Opportunistic Salpingectomy for Ovarian Cancer Prevention

02/24/2022

True or False: Opportunistic salpingectomy at the time of elective cholecystectomy is not a cost-effective strategy to prevent ovarian cancer among average risk women.

True or False: Opportunistic...

02/24/2022

Journal of Clinical Pathways

Quiz

Quiz: PARP Inhibitors in Patients With Epithelial Ovarian Cancer

12/14/2021

True or False: Findings from a study assessing patients’ and oncologists’ preferences for second-line PARP inhibitor maintenance in epithelial ovarian cancer suggest that the PFS gains are worth the toxicity risk.

True or False: Findings from a...

12/14/2021

Journal of Clinical Pathways

Quiz

Quiz: Differences Between Available PARP Inhibitors for Ovarian Cancer

12/08/2021

True or False: There are differences between available PARP inhibitors in the risk of experiencing a clinical event of interest, likelihood of dose modifications, ability to receive continuous therapy, health care resource utilization, and...

True or False: There are...

12/08/2021

Journal of Clinical Pathways

Quiz

Quiz: Olaparib Maintenance for Ovarian Cancer

10/06/2021

True or False: Olaparib maintenance is both safe and effective for the treatment of BRCA-mutated recurrent ovarian cancer.

True or False: Olaparib...

10/06/2021

Journal of Clinical Pathways

Quiz

Quiz: Cost-Effectiveness of Olaparib vs Niraparib for the Treatment of Ovarian Cancer

09/24/2021

True or False: Olaparib is more cost-effective than niraparib for maintenance therapy in patients with recurrent platinum-sensitive ovarian cancer.

True or False: Olaparib is more...

09/24/2021

Journal of Clinical Pathways

Quiz

Quiz: First-Line Maintenance Therapy for Ovarian Cancer

08/05/2021

True or False: First-line maintenance therapy use for ovarian cancer has decreased over time, particularly among patients with biomarker guidance.

True or False: First-line...

08/05/2021

Journal of Clinical Pathways

Quiz

Quiz: Cost-Effectiveness of VTE Prophylaxis for Ovarian Cancer

07/27/2021

True or False: Venous thromboembolism prophylaxis with direct oral anticoagulants during neoadjuvant chemotherapy for ovarian cancer is more costly but more effective than no therapy.

True or False: Venous...

07/27/2021

Journal of Clinical Pathways

Quiz

Quiz: Is First-Line Niraparib Maintenance Cost-Effective for Patients With Advanced Ovarian Cancer?

04/16/2021

Journal of Clinical Pathways

Quiz

Quiz: How Can We Optimize Genetic Testing for Breast and Ovarian Cancer?

03/17/2021

Journal of Clinical Pathways

Current Issue

June 2024

Volume 10

Issue 3

Current Issue

Issue Archive

Special Reports

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Winston Wong, PharmD

Gordon Kuntz

Robin T Zon, MD, FACP, FASCO

2021 Care Pathways Working Group

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

$Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma$

Special Report

Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma

01/14/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Ovarian Cancer Quiz

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products